Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04631107 · ClinicalTrials.gov registry record · Phase 2
AD109 Dose Finding in Mild to Moderate OSA
A Phase 2 study, sponsored by Apnimed.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT04631107 is a Phase 2 study that has completed, run by Apnimed. The registered enrollment target is 32 participants.
The verdict
NCT04631107, a Phase 2 study, has completed, sponsored by Apnimed.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a randomized, 3-period, placebo-controlled, crossover, phase 2 clinical study to examine the efficacy and safety of 2 doses of AD109 vs placebo in patients with mild obstructive sleep apnea.
Interventions
- DRUG AD109 dose1- A
- DRUG AD109 dose2- B
- DRUG Placebo- C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2020-12-22 |
| Est. Completion | 2021-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04631107
The ClinicalTrials.gov registry entry for NCT04631107 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Apnimed, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which AD109 dose1- A is the first listed.
NCT04631107 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04631107 about?
NCT04631107 is a clinical study titled "AD109 Dose Finding in Mild to Moderate OSA". This is a randomized, 3-period, placebo-controlled, crossover, phase 2 clinical study to examine the efficacy and safety of 2 doses of AD109 vs placebo in patients with mild obstructive sleep apnea.
What is the current status of trial NCT04631107?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2020-12-22. Estimated completion is 2021-05-31.
What interventions are being tested in trial NCT04631107?
The interventions under investigation include: AD109 dose1- A (DRUG), AD109 dose2- B (DRUG), Placebo- C (DRUG).
Who is sponsoring clinical trial NCT04631107?
This trial is sponsored by Apnimed, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.